Discovery of BGM1812, a Novel Dual Amylin and Calcitonin Receptor Agonist for Obesity Treatment Journal of Medicinal Chemistry Does this chart seem accurate? : r cagrilintide Once weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double blind, placebo controlled and active controlled, dose finding phase 2 trial The Lancet . , One of the biggest mistakes I see is assuming that if someone cannot tolerate a GLP 1, there are no other options. Thats